301 related articles for article (PubMed ID: 29470253)
1. Management of nontuberculous mycobacterial pulmonary disease.
Adelman MH; Addrizzo-Harris DJ
Curr Opin Pulm Med; 2018 May; 24(3):212-219. PubMed ID: 29470253
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic treatment for nontuberculous mycobacterial lung disease.
Kang YA; Koh WJ
Expert Rev Respir Med; 2016; 10(5):557-68. PubMed ID: 26967761
[TBL] [Abstract][Full Text] [Related]
3. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
[No Abstract] [Full Text] [Related]
4. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease.
Kwon YS; Koh WJ
J Korean Med Sci; 2016 May; 31(5):649-59. PubMed ID: 27134484
[TBL] [Abstract][Full Text] [Related]
5. Management of nontuberculous mycobacterial (NTM) lung disease.
Philley JV; Griffith DE
Semin Respir Crit Care Med; 2013 Feb; 34(1):135-42. PubMed ID: 23460013
[TBL] [Abstract][Full Text] [Related]
6. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.
Moon SM; Jhun BW; Baek SY; Kim S; Jeon K; Ko RE; Shin SH; Lee H; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ
Respir Med; 2019 May; 151():1-7. PubMed ID: 31047103
[TBL] [Abstract][Full Text] [Related]
7. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Kwon YS; Daley CL; Koh WJ
Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
[No Abstract] [Full Text] [Related]
8. Introducing the new BTS Guideline: Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Haworth CS; Floto RA
Thorax; 2017 Nov; 72(11):969-970. PubMed ID: 29054887
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for a one-year improvement in nontuberculous mycobacterial pulmonary disease: An 11-year retrospective and multicenter study.
Cadelis G; Ducrot R; Bourdin A; Rastogi N
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005841. PubMed ID: 28787454
[TBL] [Abstract][Full Text] [Related]
10. [Nontuberculous mycobacterial pulmonary disease].
Ringshausen FC; Rademacher J
Internist (Berl); 2016 Feb; 57(2):142-52. PubMed ID: 26810111
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective.
Koh WJ; Kwon OJ; Lee KS
J Korean Med Sci; 2005 Dec; 20(6):913-25. PubMed ID: 16361797
[TBL] [Abstract][Full Text] [Related]
12. Nontuberculous mycobacteria infections in immunosuppressed hosts.
Henkle E; Winthrop KL
Clin Chest Med; 2015 Mar; 36(1):91-9. PubMed ID: 25676522
[TBL] [Abstract][Full Text] [Related]
13. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W
Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454
[No Abstract] [Full Text] [Related]
14. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.
Velagapudi M; Sanley MJ; Ased S; Destache C; Malesker MA
Am J Health Syst Pharm; 2022 Mar; 79(6):437-445. PubMed ID: 34788375
[TBL] [Abstract][Full Text] [Related]
16. Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720.
Winthrop KL; Flume P; Hamed KA
Expert Rev Anti Infect Ther; 2023; 21(11):1177-1187. PubMed ID: 37862563
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Martiniano SL; Wagner BD; Levin A; Nick JA; Sagel SD; Daley CL
Chest; 2017 Oct; 152(4):800-809. PubMed ID: 28483608
[TBL] [Abstract][Full Text] [Related]
18. Treatment of slowly growing mycobacteria.
Philley JV; Griffith DE
Clin Chest Med; 2015 Mar; 36(1):79-90. PubMed ID: 25676521
[TBL] [Abstract][Full Text] [Related]
19. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
[TBL] [Abstract][Full Text] [Related]
20. Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report.
Henkle E; Aksamit T; Barker A; Daley CL; Griffith D; Leitman P; Leitman A; Malanga E; Marras TK; Olivier KN; Prevots DR; Prieto D; Quittner AL; Skach W; Walsh JW; Winthrop KL;
Ann Am Thorac Soc; 2016 Sep; 13(9):S379-84. PubMed ID: 27627485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
